Moriceau et al. demonstrated recently that RAD001 (everolimus) a new oral mTOR inhibitor, inhibited osteosarcoma cell proliferation and its combination with zoledronic acid reduced tumour development in murine models of mixed osteoblastic/osteolytic or undifferentiated osteosarcoma [7]. Here, MTOR is linked to osteosarcoma.